Showing 701 - 720 results of 824 for search '"Academy of Medical Sciences"', query time: 0.09s Refine Results
  1. 701
  2. 702
  3. 703
  4. 704
  5. 705
  6. 706
  7. 707
  8. 708
  9. 709
  10. 710
  11. 711
  12. 712
  13. 713

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  14. 714
  15. 715
  16. 716
  17. 717
  18. 718
  19. 719
  20. 720

    Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

    Published 2025-02-01
    “…Yuqing Cui,1,2 Xin Liu,1,2 Sizhou Feng1,2 1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People’s Republic of China; 2Tianjin Institutes of Health Science, Tianjin, 300020, People’s Republic of ChinaCorrespondence: Sizhou Feng, Email doctor_szhfeng@163.comPurpose: Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines for empirical treatment of febrile neutropenia (FN), there have been significant shifts in pathogen profiles and emerging challenges in treatment. …”
    Get full text
    Article